Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.61 |
| ▸ | SELP | P16109 | 6/20 | 0.49 |
| ▸ | SELL | P14151 | 3/20 | 0.49 |
| ▸ | SELE | P16581 | 3/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.44 |
| ▸ | VEGFA | P15692 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8193481 | 1.00 | APP (0.61) | APPSELPSELLSELECETP | |
| SCHEMBL8690501 | 1.00 | APP (0.61) | APPSELPSELLSELECETP | |
| SCHEMBL8193479 | 1.00 | APP (0.61) | APPSELPSELLSELECETP | |
| SCHEMBL8685816 | 1.00 | APP (0.61) | APPSELPSELLSELECETP | |
| SCHEMBL5959885 | 1.00 | APP (0.61) | APPSELPSELLSELECETP | |
| SCHEMBL5959831 | 1.00 | APP (0.61) | APPSELPSELLSELECETP | |
| SCHEMBL8685746 | 1.00 | APP (0.61) | APPSELPSELLSELECETP | |
| SCHEMBL5959829 | 1.00 | APP (0.61) | APPSELPSELLSELECETP | |
| SCHEMBL8506473 | 1.00 | APP (0.61) | APPSELPSELLSELECETP | |
| SCHEMBL5959887 | 1.00 | APP (0.61) | APPSELPSELLSELECETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4531812-A1 | LIPID NANOCARRIER VACCINE | Royal Melbourne Institute of Technology (AU) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023225722-A1 | LIPID NANOCARRIER VACCINE | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2023-11-30 | — | — | WO | disclosed |
| EP-4087853-B1 | NEW IMMUNOSTIMULATORS AND USE THEREOF IN IMMUNOTHERAPY | UNIV NANTES (FR) | 2023-10-18 | — | — | EP | disclosed |
| US-20230088717-A1 | NEW IMMUNOSTIMULATORS AND USE THEREOF IN IMMUNOTHERAPY | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-03-23 | — | — | US | disclosed |
| EP-4087853-A1 | NEW IMMUNOSTIMULATORS AND USE THEREOF IN IMMUNOTHERAPY | NANTES UNIVERSITÉ (FR) | 2022-11-16 | — | — | EP | disclosed |
| US-8053417-B2 | Mucosal adjuvants elicit strong balanced or adjusted immune response of humoral, cellular components; prophylaxis or treatment of infectious diseases or cancer; non-toxic; employed with a wide variety of active ingredients to be assisted in conventional or novel vaccines | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2011-11-08 | — | — | US | disclosed |
| EP-1940464-B1 | HEXOSYLCERAMIDES AS ADJUVANTS AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | HELMHOLTZ INFEKTIONSFORSCHUNG (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-20080206319-A1 | Hexosylceramides as Adjuvants and Their Uses in Pharmaceutical Compositions | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1776963-A1 | Hexosylceramides as adjuvants and their uses in pharmaceutical compositions | GBF-GESELLSCHAFT FÜR BIOTECHNOLOGISCHE FORSCHUNG MBH (DE) | 2007-04-25 | — | — | EP | disclosed |
| US-5780441-A | WATER-SOLUBLE CEREBROSIDES HAVING UTILITY AS ANTIUMOR AGENTS, BONE MARROW CELL-PROLIFERATION PROMOTERS AND INNUMOSTIMULANTS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1998-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230088717-A1 | NEW IMMUNOSTIMULATORS AND USE THEREOF IN IMMUNOTHERAPY | KLF10, ICOS, PBK | APP 4149/4885SELP 1034/4885SELL 773/4885 |
| US-20080206319-A1 | Hexosylceramides as Adjuvants and Their Uses in Pharmaceutical Compositions | MAN2B2, HEXA, SGMS2 | APP 2318/4885SELP 1022/4885SELL 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.